Journal of Clinical Medicine Research

Objective: To investigate the effect of sintilimab combined with cisplatin + pemetrexed chemotherapy regimen on tumor markers in patients with non-small cell lung cancer (NSCLC). Methods: A total of 68 NSCLC patients in the Oncology Department of Sichuan Provincial Jiaotong Hospital from June 2023 to June 2025 were selected and randomly divided into two groups using a random number table method. The control group (34 cases) was treated with cisplatin + pemetrexed chemotherapy regimen, and the experimental group (34 cases) was treated with sintilimab injection on the basis of the control group's regimen. The changes in tumor marker levels, therapeutic efficacy and safety were compared between the two groups. Results: After treatment, the levels of the above tumor markers in both groups were significantly lower than those before treatment, and the levels of each index in the experimental group were significantly lower than those in the control group, with statistically significant differences (P<0.05); there was no statistically significant difference in adverse reaction indexes between the two groups (P>0.05). Conclusion: The application of sintilimab combined with cisplatin + pemetrexed chemotherapy regimen in NSCLC patients can significantly reduce the expression levels of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE) and other tumor markers, improve the clinical objective response rate and disease control rate, with considerable safety, which is worthy of clinical promotion.